sealed with aluminum flip-off type caps. FVIIa may be produced as disclosed in EP patent No. 200,421.

CLAIMS

1. A pharmaceutical composition for parenteral administration, which comprises a peptide and dimethyl sulfone.

2. A pharmaceutical composition according to claim 1, wherein the amount of dimethyl sulfone is of from 40 to 400 mM.

3. A pharmaceutical composition according to claim 2, wherein amount of dimethyl sulfone is of from 125 to 350 mM.

4. A pharmaceutical composition according to claim 1, wherein the composition is a solution.

5. A pharmaceutical composition according to claim 1, wherein the composition is a suspension.

6. A pharmaceutical composition according to claim 1, which is suitable for administration by injection or infusion.

7. A pharmaceutical composition according to claim 6, which is suitable for subcutaneous administration.

8. A pharmaceutical composition according to claim 6, which is suitable for intramuscular administration.

9. A pharmaceutical composition according to claim 6, which is suitable for intravenous administration.

10. A pharmaceutical composition according to claim 1, which is suitable for pulmonal administration.

11. A pharmaceutical composition according to claim 1, which is suitable for ophthalmic administration or topical administration.

12. A pharmaceutical composition according to claim 1, wherein the peptide is human growth hormone, GLP-1, GLP-2, insulin, Factor VIIa, Factor VIII, erythropoeitin (EPO), glucagon, interleukin, such as interleukin-2 (IL-2), interferon-α or interferon-β, or an analogue thereof, or a derivative of any such peptide or analogue.

13. A pharmaceutical composition according to claim 12, wherein the peptide is human insulin or an analogue thereof, or a derivative of human insulin or the human insulin analogue.

14. A pharmaceutical composition according to claim 13, wherein the peptide is human insulin.

15. A pharmaceutical composition according to claim 13, wherein the peptide is Asp(B28)-human insulin.

16. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B28) Pro(B29)-human insulin.

17. A pharmaceutical composition according to claim 13, wherein the peptide is Lys(B3) Glu(B29)-human insulin.

18. A pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$-tetradecanoyl des (B30)-human insulin.

19. A pharmaceutical composition according to claim 13, wherein the peptide is Gly(A21) Arg(B31) Arg(B32)-human insulin.

20. A pharmaceutical composition according to claim 13, wherein the peptide is $N^{\varepsilon B29}$–litocholoyl-γ-glutamyl des (B30)-human insulin.

21. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(8)-human GLP-1.

22. A pharmaceutical composition according to claim 12, wherein the peptide is Arg(34), N-ε-(γ-Glu(N-α-hexadecanoyl))-Lys(26)-human GLP-1(7-37)OH.

23. A pharmaceutical composition according to claim 12, wherein the peptide is Gly(2)-human GLP-2.